Business Wire

CA-ALTIUM

27.4.2022 08:32:11 CEST | Business Wire | Press release

Share
Nexar Adds Industry Demand Index to Electronic Design to Delivery Index (EDDI) Report

Nexar, a business unit of Altium LLC, (ASX:ALU), has announced today the addition of the Industry Demand Index to the Spectra Electronic Design to Delivery Index (EDDI) report. Published monthly as a free subscription, EDDI gives in-depth analysis and actionable data intelligence into what is happening in the electronics component industry by comparing current insights with information sourced from more than two years of component history of tens of millions of parts.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426006368/en/

Spectra is Nexar’s suite of electronic industry data intelligence offerings and products that helps businesses better anticipate supply chain challenges and opportunities. Spectra’s inaugural EDDI report, released in February 2022, offered the Industry Supply Index, which provides insights into the supply chain industry. With the addition of the Industry Demand Index to the latest EDDI, the data provides a clear look into component interest and how that will affect supply trends. These combined signals give a clear picture of the current supply and demand landscape that businesses can use to make smarter component selection decisions.

“The Altium ecosystem meets at the intersection of the design, supply chain and manufacturing domains. Our unique industry viewpoint positions our Nexar business unit to provide actionable insights on electronic component trends,” says Daniel Schoenfelder, Head of Nexar Sales and Octopart. “We are proud that EDDI is now the best free source of supply and demand business intelligence for stakeholders across the electronic component industry.”

A recent global survey conducted by IPC found that electronics manufacturers continue to be impacted by global shortages in semiconductors and other components and parts, which is contributing to production delays and uncertainty in the industry. As a result of the uncertainties, stakeholders need business intelligence to make better decisions across the design, supply chain, and manufacturing spectrum. Businesses can utilize EDDI in their engineering and business workflows to navigate issues they encounter with their bill of materials (BOM).

The EDDI is the only free industry report that provides comprehensive business intelligence on market conditions that can be leveraged by all stakeholders in the electronic component space. Spectra’s business intelligence offerings will continue to provide unparalleled transformational insights to the electronics industry.

The latest EDDI containing both supply and demand indices is now available on nexar.com/spectra/eddi , with new reports released each month. Subscribing to the EDDI guarantees to receive the most accurate supply chain insights sent directly to your inbox on a monthly basis.

To learn more about Spectra’s suite of data intelligence products or to get access to the latest EDDI, visit nexar.com/spectra .

About Nexar

Nexar is a Business Unit of Altium, LLC (ASX:ALU ). Altium, LLC, is a global software company headquartered in San Diego, California, who are accelerating the pace of innovation through electronics. For over 30 years, Altium has been delivering software that maximizes the productivity of PCB designers and electrical engineers. From individual inventors to multinational corporations, more PCB designers and engineers choose Altium software to design and realize electronics-based products.

Social Media:

https://www.facebook.com/AltiumOfficial/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye